MARKER THERAPEUTICS, INC.

(MRKR)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
0.3543 USD   -2.58%
08/11MARKER THERAPEUTICS : Reports Q2 2022 Operating and Financial Results - Form 8-K
PU
08/11MARKER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/11Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Marker Therapeutics Shares Climb Over 50% After FDA Approves IND for MT-601

08/05/2022 | 11:49am EDT

By Stephen Nakrosis


Shares of Marker Therapeutics Inc. were trading higher Friday, continuing momentum from the after-hours market Thursday following news the U.S. Food and Drug Administration approved the company's investigational new drug application for MT-601 to treat certain patients with non-Hodgkin lymphoma.

At 11:26 a.m. ET, the company's stock had risen 55% to trade at 51 on Nasdaq. Volume at the time topped 51.1 million shares, above the stock's 65-day average volume of 373,289 shares.

Following the news of the FDA approval Thursday, Marker shares rose in the late-trading market. The stock closed Thursday's regular session at 33 cents and opened at 60 cents on Friday.

Peter Hoang, the company's president and chief executive, said: "FDA clearance of our IND for MT-601 is a significant milestone as we advance our pipeline in a number of company-sponsored trials." He said that MT-601 targets six tumor-associated antigens highly expressed in lymphoma, and Marker looks plans to initiate a company-sponsored Phase 1 study next year.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

08-05-22 1149ET

Stocks mentioned in the article
ChangeLast1st jan.
MARKER THERAPEUTICS, INC. -2.58% 0.3543 Delayed Quote.-62.71%
NASDAQ COMPOSITE -1.25% 12938.12 Real-time Quote.-16.25%
All news about MARKER THERAPEUTICS, INC.
08/11MARKER THERAPEUTICS : Reports Q2 2022 Operating and Financial Results - Form 8-K
PU
08/11MARKER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/11Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/11Marker Therapeutics Reports Q2 2022 Operating and Financial Results
AQ
08/08Top Premarket Decliners
MT
08/05Marker Therapeutics Shares Climb Over 50% After FDA Approves IND for MT-601
DJ
08/05Wall Street Tumbles Pre-Bell as US Economy Adds 528,000 Jobs
MT
08/05Top Premarket Gainers
MT
08/04MARKER THERAPEUTICS : Announces FDA Clearance of IND for MT-601, the six-antigen targeted ..
PU
08/04MARKER THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
More news
Analyst Recommendations on MARKER THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 2,63 M - -
Net income 2022 -41,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,72x
Yield 2022 -
Capitalization 29,6 M 29,6 M -
Capi. / Sales 2022 11,3x
Capi. / Sales 2023 24,7x
Nbr of Employees 56
Free-Float 79,7%
Chart MARKER THERAPEUTICS, INC.
Duration : Period :
Marker Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MARKER THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 0,35 $
Average target price 2,17 $
Spread / Average Target 512%
EPS Revisions
Managers and Directors
Peter L. Hoang President, Chief Executive Officer & Director
Anthony H. Kim Chief Financial Officer
Norman David Eansor Independent Chairman
Juan F. Vera Director, Chief Operating & Scientific Officer
Tsvetelina Pencheva Hoang Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MARKER THERAPEUTICS, INC.-62.71%30
MODERNA, INC.-37.79%65 706
IQVIA HOLDINGS INC.-13.27%45 640
LONZA GROUP AG-26.68%43 587
SEAGEN INC.10.47%31 450
ALNYLAM PHARMACEUTICALS, INC.31.58%27 384